Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.

Kumar, Princy

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. [electronic resource] - BMC infectious diseases Jun 2013 - 269 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1471-2334

10.1186/1471-2334-13-269 doi


Adolescent
Adult
Aged
Alkynes
Anti-HIV Agents--therapeutic use
Benzoxazines--therapeutic use
Biomarkers--blood
C-Reactive Protein--metabolism
Carbamates--therapeutic use
Cyclopropanes
Dideoxynucleosides--therapeutic use
Drug Combinations
Female
Fibrin Fibrinogen Degradation Products--metabolism
Fibrinogen--metabolism
Furans
HIV Infections--blood
Humans
Interleukin-6--blood
Lamivudine--therapeutic use
Male
Middle Aged
Organophosphates--therapeutic use
Plasminogen--metabolism
Prospective Studies
Ritonavir--therapeutic use
Sulfonamides--therapeutic use
Vascular Cell Adhesion Molecule-1--blood
Young Adult